Skip to main content
LLYEli Lilly and CompanyBuy Wait6.4·$1116.20-0.61%

Eli Lilly and (LLY) Q2 2026 earnings — TrendMatrix coverage

BEAT+27.3% vs estimateEPS $8.38 vs $6.58 estVerdict HoldBuy (Wait)

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$8.38
Estimate
$6.58
Surprise
+27.3%
Revenue (period 2026-06-30)
$22.97B
Score at report (before → after)
6.46.6/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Eli Lilly and (LLY) beat the $6.58 estimate with diluted EPS of $8.38 — a large 27.3% upside surprise. TrendMatrix's engine moved from Hold (6.4/10) to Buy (Wait) at 6.6/10 after the report.

Current read · as of 2026-09-13

Where TrendMatrix's rating stands now

TrendMatrix currently rates LLY Buy (Wait) at 6.4/10.

4 of the last 4 quarters beat the estimate; this quarter's +27.3% surprise compares with a +20.4% four-quarter average. Next scheduled report: 2026-10-29.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Thin upside margin: 6.4%
  • Leverage penalty (D/E 1.6): -1.0
  • Negative momentum

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$1116.20
Entry target
$1087.92
Price target
$1186.80
Stop
$1032.36
Upside to target
+6.3%
Reward-to-risk
1.3:1

The stock trades at 37.5× trailing but 23.6× forward earnings — consensus estimates already build in a substantial earnings recovery.

Risk check: RSI 2 — a level conventionally read as oversold.

Model outputs from TrendMatrix’s engine as of 2026-09-13 — shown for context, not personalized investment advice.

Healthcare context

LLY at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Drug Manufacturers - General
Market cap
$994.92B
P/E (fwd)
23.6
P/E (ttm)
37.5
52-week range
$712.05$1292.65
Off 52-week high
13.7%
RSI (14)
2
Volume vs avg
0.75×
Score today
6.4/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks LLY Earnings Q2 2026 earnings